- Home
- GNPX vs MGRX Comparison
GNPX vs MGRX Comparison
Compare GNPX & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- MGRX
- Stock Information
- Founded
- GNPX 2009
- MGRX 2021
- Country
- GNPX United States
- MGRX United States
- Employees
- GNPX N/A
- MGRX N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- MGRX Computer Software: Prepackaged Software
- Sector
- GNPX Health Care
- MGRX Technology
- Exchange
- GNPX Nasdaq
- MGRX Nasdaq
- Market Cap
- GNPX 7.5M
- MGRX 8.1M
- IPO Year
- GNPX 2018
- MGRX 2023
- Fundamental
- Price
- GNPX $0.29
- MGRX $2.04
- Analyst Decision
- GNPX
- MGRX
- Analyst Count
- GNPX 0
- MGRX 0
- Target Price
- GNPX N/A
- MGRX N/A
- AVG Volume (30 Days)
- GNPX 1.8M
- MGRX 204.7K
- Earning Date
- GNPX 05-12-2025
- MGRX 05-15-2025
- Dividend Yield
- GNPX N/A
- MGRX N/A
- EPS Growth
- GNPX N/A
- MGRX N/A
- EPS
- GNPX N/A
- MGRX N/A
- Revenue
- GNPX N/A
- MGRX $511,084.00
- Revenue This Year
- GNPX N/A
- MGRX N/A
- Revenue Next Year
- GNPX N/A
- MGRX N/A
- P/E Ratio
- GNPX N/A
- MGRX N/A
- Revenue Growth
- GNPX N/A
- MGRX N/A
- 52 Week Low
- GNPX $0.22
- MGRX $1.32
- 52 Week High
- GNPX $3.97
- MGRX $7.66
- Technical
- Relative Strength Index (RSI)
- GNPX 50.37
- MGRX 52.44
- Support Level
- GNPX $0.26
- MGRX $2.05
- Resistance Level
- GNPX $0.37
- MGRX $2.28
- Average True Range (ATR)
- GNPX 0.04
- MGRX 0.24
- MACD
- GNPX 0.00
- MGRX 0.06
- Stochastic Oscillator
- GNPX 35.04
- MGRX 57.56
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.